We need to bring R0 < 1 to treat cancer too

Genome Med. 2021 Jul 26;13(1):120. doi: 10.1186/s13073-021-00940-9.

Abstract

If each cancer cell produces on average more than one cancer cell, we see a net growth of the tumors and metastases and vice versa. We review recent clinical results for microsatellite stable metastatic colorectal cancer (MSS-mCRC) suggesting immunotherapy combinations with personalized vaccines, checkpoint inhibitors, targeted therapies, multikinase inhibitors, chemotherapies, and radiation that simultaneously slow cancer cell growth rate and enhance T cell killing rate of cancer cells may in future synergize to control the disease.

Trial registration: ClinicalTrials.gov NCT01970358 NCT03548467 NCT03739931.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor
  • Combined Modality Therapy / adverse effects
  • Combined Modality Therapy / methods
  • Disease Management*
  • Disease Susceptibility*
  • Humans
  • Immunotherapy / adverse effects
  • Immunotherapy / methods
  • Microsatellite Instability
  • Models, Theoretical*
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Neoplasms / diagnosis
  • Neoplasms / etiology*
  • Neoplasms / metabolism
  • Neoplasms / therapy*
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism
  • Tumor Microenvironment

Substances

  • Biomarkers, Tumor

Associated data

  • ClinicalTrials.gov/NCT01970358
  • ClinicalTrials.gov/NCT03548467
  • ClinicalTrials.gov/NCT03739931